Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma

David S. Priemer, Mingsheng Wang, Shaobo Zhang, Antonio Lopez-Beltran, Erik Kouba, Rodolfo Montironi, Darrell Davidson, Gregory T. MacLennan, Lisha Wang, Adeboye O. Osunkoya, Youping Deng, Robert Emerson, Liang Cheng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Small-cell carcinoma (SCC) of the urinary bladder frequently appears alongside urothelial carcinoma, suggesting common clonality. TERT promoter mutations have been recently implicated in urothelial carcinogenesis. Objective: To investigate the degree to which TERT promoter mutations are involved in SCC of the urinary bladder, the linked tumorigenesis between urothelial carcinoma and SCC of the urinary bladder, and the molecular distinctions between SCC of the urinary bladder and of the prostate. Design, setting, and participants: We investigated TERT promoter mutations in 53 cases of SCC of the urinary bladder and in 26 cases of SCC of the prostate using laboratory-based studies of tissue samples and clinical data. Outcome measurements and statistical analysis: We measured the frequency of TERT promoter mutations in SCCs of the urinary bladder and prostate, and concordance of the mutation status between concurrent urinary bladder SCC and urothelial carcinoma. Results and limitations: TERT promoter mutations were detected in 29/53 (55%) cases of urinary bladder and 0/26 (0%) cases of prostate SCC. Of 25 cases with concurrent urinary bladder SCC and non-small-cell components, all cases harbored identical TERT promoter mutation status in both phenotypes. Conclusions: TERT promoter mutations are found in more than half of urinary bladder SCCs. Mutation status is also identical in urothelial carcinoma and SCC components of concomitant malignancies, providing evidence of a common clonality. TERT promoter mutation status can differentiate SCC of the urinary bladder from prostate SCC, suggesting potential diagnostic use. Patient summary: Small-cell carcinoma of the urinary bladder shares a common clonal origin with conventional urothelial carcinoma and may arise from a heterogeneous subclone. TERT promoter mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma. Bladder small-cell carcinoma shares a common clonal origin with conventional urothelial malignancy and the small-cell carcinoma component of the malignancy may arise from a heterogenous subclone. TERT promotor mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - 2017

Fingerprint

Small Cell Carcinoma
Prostate
Urinary Bladder
Carcinoma
Mutation
Neoplasms
Cellular Structures
Carcinogenesis
Biomarkers

Keywords

  • Bladder
  • Histogenesis
  • Small-cell carcinoma
  • Telomerase reverse transcriptase (TERT)
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Urology

Cite this

@article{a83ddb44b5a6434fa77348c3bfab1dba,
title = "Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma",
abstract = "Background: Small-cell carcinoma (SCC) of the urinary bladder frequently appears alongside urothelial carcinoma, suggesting common clonality. TERT promoter mutations have been recently implicated in urothelial carcinogenesis. Objective: To investigate the degree to which TERT promoter mutations are involved in SCC of the urinary bladder, the linked tumorigenesis between urothelial carcinoma and SCC of the urinary bladder, and the molecular distinctions between SCC of the urinary bladder and of the prostate. Design, setting, and participants: We investigated TERT promoter mutations in 53 cases of SCC of the urinary bladder and in 26 cases of SCC of the prostate using laboratory-based studies of tissue samples and clinical data. Outcome measurements and statistical analysis: We measured the frequency of TERT promoter mutations in SCCs of the urinary bladder and prostate, and concordance of the mutation status between concurrent urinary bladder SCC and urothelial carcinoma. Results and limitations: TERT promoter mutations were detected in 29/53 (55{\%}) cases of urinary bladder and 0/26 (0{\%}) cases of prostate SCC. Of 25 cases with concurrent urinary bladder SCC and non-small-cell components, all cases harbored identical TERT promoter mutation status in both phenotypes. Conclusions: TERT promoter mutations are found in more than half of urinary bladder SCCs. Mutation status is also identical in urothelial carcinoma and SCC components of concomitant malignancies, providing evidence of a common clonality. TERT promoter mutation status can differentiate SCC of the urinary bladder from prostate SCC, suggesting potential diagnostic use. Patient summary: Small-cell carcinoma of the urinary bladder shares a common clonal origin with conventional urothelial carcinoma and may arise from a heterogeneous subclone. TERT promoter mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma. Bladder small-cell carcinoma shares a common clonal origin with conventional urothelial malignancy and the small-cell carcinoma component of the malignancy may arise from a heterogenous subclone. TERT promotor mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma.",
keywords = "Bladder, Histogenesis, Small-cell carcinoma, Telomerase reverse transcriptase (TERT), Tumor heterogeneity",
author = "Priemer, {David S.} and Mingsheng Wang and Shaobo Zhang and Antonio Lopez-Beltran and Erik Kouba and Rodolfo Montironi and Darrell Davidson and MacLennan, {Gregory T.} and Lisha Wang and Osunkoya, {Adeboye O.} and Youping Deng and Robert Emerson and Liang Cheng",
year = "2017",
doi = "10.1016/j.euf.2017.03.007",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Small-cell Carcinomas of the Urinary Bladder and Prostate

T2 - TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma

AU - Priemer, David S.

AU - Wang, Mingsheng

AU - Zhang, Shaobo

AU - Lopez-Beltran, Antonio

AU - Kouba, Erik

AU - Montironi, Rodolfo

AU - Davidson, Darrell

AU - MacLennan, Gregory T.

AU - Wang, Lisha

AU - Osunkoya, Adeboye O.

AU - Deng, Youping

AU - Emerson, Robert

AU - Cheng, Liang

PY - 2017

Y1 - 2017

N2 - Background: Small-cell carcinoma (SCC) of the urinary bladder frequently appears alongside urothelial carcinoma, suggesting common clonality. TERT promoter mutations have been recently implicated in urothelial carcinogenesis. Objective: To investigate the degree to which TERT promoter mutations are involved in SCC of the urinary bladder, the linked tumorigenesis between urothelial carcinoma and SCC of the urinary bladder, and the molecular distinctions between SCC of the urinary bladder and of the prostate. Design, setting, and participants: We investigated TERT promoter mutations in 53 cases of SCC of the urinary bladder and in 26 cases of SCC of the prostate using laboratory-based studies of tissue samples and clinical data. Outcome measurements and statistical analysis: We measured the frequency of TERT promoter mutations in SCCs of the urinary bladder and prostate, and concordance of the mutation status between concurrent urinary bladder SCC and urothelial carcinoma. Results and limitations: TERT promoter mutations were detected in 29/53 (55%) cases of urinary bladder and 0/26 (0%) cases of prostate SCC. Of 25 cases with concurrent urinary bladder SCC and non-small-cell components, all cases harbored identical TERT promoter mutation status in both phenotypes. Conclusions: TERT promoter mutations are found in more than half of urinary bladder SCCs. Mutation status is also identical in urothelial carcinoma and SCC components of concomitant malignancies, providing evidence of a common clonality. TERT promoter mutation status can differentiate SCC of the urinary bladder from prostate SCC, suggesting potential diagnostic use. Patient summary: Small-cell carcinoma of the urinary bladder shares a common clonal origin with conventional urothelial carcinoma and may arise from a heterogeneous subclone. TERT promoter mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma. Bladder small-cell carcinoma shares a common clonal origin with conventional urothelial malignancy and the small-cell carcinoma component of the malignancy may arise from a heterogenous subclone. TERT promotor mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma.

AB - Background: Small-cell carcinoma (SCC) of the urinary bladder frequently appears alongside urothelial carcinoma, suggesting common clonality. TERT promoter mutations have been recently implicated in urothelial carcinogenesis. Objective: To investigate the degree to which TERT promoter mutations are involved in SCC of the urinary bladder, the linked tumorigenesis between urothelial carcinoma and SCC of the urinary bladder, and the molecular distinctions between SCC of the urinary bladder and of the prostate. Design, setting, and participants: We investigated TERT promoter mutations in 53 cases of SCC of the urinary bladder and in 26 cases of SCC of the prostate using laboratory-based studies of tissue samples and clinical data. Outcome measurements and statistical analysis: We measured the frequency of TERT promoter mutations in SCCs of the urinary bladder and prostate, and concordance of the mutation status between concurrent urinary bladder SCC and urothelial carcinoma. Results and limitations: TERT promoter mutations were detected in 29/53 (55%) cases of urinary bladder and 0/26 (0%) cases of prostate SCC. Of 25 cases with concurrent urinary bladder SCC and non-small-cell components, all cases harbored identical TERT promoter mutation status in both phenotypes. Conclusions: TERT promoter mutations are found in more than half of urinary bladder SCCs. Mutation status is also identical in urothelial carcinoma and SCC components of concomitant malignancies, providing evidence of a common clonality. TERT promoter mutation status can differentiate SCC of the urinary bladder from prostate SCC, suggesting potential diagnostic use. Patient summary: Small-cell carcinoma of the urinary bladder shares a common clonal origin with conventional urothelial carcinoma and may arise from a heterogeneous subclone. TERT promoter mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma. Bladder small-cell carcinoma shares a common clonal origin with conventional urothelial malignancy and the small-cell carcinoma component of the malignancy may arise from a heterogenous subclone. TERT promotor mutations may have utility as a differential biomarker for determining the primary site of a genitourinary small-cell carcinoma.

KW - Bladder

KW - Histogenesis

KW - Small-cell carcinoma

KW - Telomerase reverse transcriptase (TERT)

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85016469593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016469593&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2017.03.007

DO - 10.1016/j.euf.2017.03.007

M3 - Article

C2 - 28753872

AN - SCOPUS:85016469593

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -